Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Bullboard Posts
Post by alixx11on Feb 11, 2010 8:46am
498 Views
Post# 16774207

Jay Taylor (1/30/2010)

Jay Taylor (1/30/2010)

Jay Taylor's Energy & Energy Tech Stocks (01/30/2010)

"In your editor's view, NioGold Mining (TSX-V: NOX) has the potential to continue building its gold resource into the multi-million ounce range given following factors:

  • Gold mineralization along the major faults zones in Quebec and Ontario extend to great depths. So far, most of the resources have been calculated to a depth of 200 meters with the deepest holes going to 630 meters, which is still very shallow compared to the depth from which gold has been mined in these systems.
  • There are many zones on surface that have yet to be tested. Most notable in that regard is the area between the Marban Mine and the Malartic Mine to the North.
  • Other Quebec Projects in the Area not show on the map also have great exploration potential and can be focused on later after the company brings its Malartic area property up to an optimum level where its economics come into focus.

With 64 million shares outstanding and a price of C
.33, thiscompany has a market cap of only about C$21 million and nearly 1million ounces of gold in the ground. Those ounces can risedramatically with an aggressive drill program being planned over thenext year or so. We can't generally view a 'C' progress company withthe same level of comfort we usually assign to a producer or a companythat has established solid economic potential. But, given its lowmarket cap, likely ability to grow its resources substantially in anarea that arguably has the most pro-mining government in the world andthat has all the infrastructure required for mining, we think NioGoldoffers speculative investors great upside potential from its ongoingexploration efforts, assuming as we do that the gold bull market willremain in place for at least several more years."
Bullboard Posts